• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

What is the diameter of a fibrin fiber?
CONCLUSION: We performed a systematic, multitechnique survey assessing fibrin fiber diameters under a range of biochemical conditions. The similarity in the diameter values obtained using SEM and superresolution imaging suggests that drying and fixation during SEM sample preparation do not dramatically alter fiber cross-sections. Congruence, under certain conditions, between diameter values obtained using SEM, superresolution fluorescence imaging, and turbidimetry demonstrates the feasibility of a fibrin diameter standardization project.PMID:37601015 | PMC:PMC10439396 | DOI:10.1016/j.rpth.2023.100285
Source: Thrombosis and Haemostasis - August 21, 2023 Category: Hematology Authors: Heather A Belcher Martin Guthold Nathan E Hudson Source Type: research

Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease
DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2.PMID:36284639 | PMC:PMC9585384 | DOI:10.1002/rth2.12814
Source: Thrombosis and Haemostasis - October 26, 2022 Category: Hematology Authors: Erika Tarasco Anne Sophie von Krogh Radomira Hrdlickova Thomas R Braschler Teresa Iwaniec Paul N Kn öbl Eriko Hamada Oleg Pikovsky Stefan Farese Odit Gutwein Petr Kessler Nina H Schultz Charis von Auer Jerzy Windyga Kenneth Friedman Ingrid Hrachovinova J Source Type: research

Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis
CONCLUSIONS: This study demonstrates that clot-targeted MH can enhance the thrombolysis of contracted human blood clots and can be safely applied to enhance the timeframe in which thrombolysis is effective.PMID:35950914 | DOI:10.1111/jth.15846
Source: Thrombosis and Haemostasis - August 11, 2022 Category: Hematology Authors: David Cabrera Maneea Eizadi Sharifabad Jacob A Ranjbar Neil D Telling Alan G S Harper Source Type: research

Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk.
CONCLUSIONS: Results support the importance of the F7 and PROCR loci on variation in circulating FVIIa and FVIIa-AT. Findings suggest FVIIa is a risk factor for ischemic stroke in older adults while higher FVIIa-AT may reflect mortality risk. This article is protected by copyright. All rights reserved. PMID: 29112333 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 7, 2017 Category: Hematology Authors: Olson NC, Raffield LM, Lange LA, Lange EM, Longstreth WT, Chauhan G, Debette S, Seshadri S, Reiner AP, Tracy RP Tags: J Thromb Haemost Source Type: research

Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates.
Abstract Factor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To date, no systematic information is available about the substrate specificity of FSAP. Applying phage display and positional scanning substrate combinatorial library (PS-SCL) approaches we have characterised the specificity of FSAP towards small peptides. Results were evaluated in the context of known protein substrates as well as molecular modelling of the peptides in the active site of FSAP....
Source: Thrombosis and Haemostasis - July 20, 2017 Category: Hematology Authors: Kara E, Manna D, Løset GÅ, Schneider EL, Craik CS, Kanse S Tags: Thromb Haemost Source Type: research

Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
Abstract We tested the hypothesis that plasma fibrin clot structure/function is unfavourably altered in patients with antiphospholipid syndrome (APS). Ex vivo plasma clot permeability, turbidity and susceptibility to lysis were determined in 126 consecutive patients with APS enrolled five months or more since thrombotic event vs 105 controls. Patients with both primary and secondary APS were characterized by 11% lower clot permeability (p<0.001), 4.8% shorter lag phase (p<0.001), 10% longer clot lysis time (p<0.001), and 4.7% higher maximum level of D-dimer released from clots (p=0.02) as compared to the ...
Source: Thrombosis and Haemostasis - March 20, 2014 Category: Hematology Authors: Celinska-Lowenhoff M, Iwaniec T, Padjas A, Musial J, Undas A Tags: Thromb Haemost Source Type: research